Clinical Trial Update: A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 multiple-dose escalation study of ASKP1240 in adults with moderate-to-severe plaque psoriasis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ASKP1240

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED